Clinical trials: sponsored by Novartis Pharmaceuticals
Severe Malaria
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
The purpose of this study was to identify the safe and effective dose of intravenous cipargamin in participants with moderately severe and severe malaria.
- Trial name
- NCT04675931
- Testing
- Cipargamin, IV Artesunate, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 254 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis
Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis
This was a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating intra-articular LNA043 in patients with knee osteoarthritis.
- Trial name
- ONWARDS (NCT04864392)
- Testing
- LNA043
- Where
- 75 sites in United States, Argentina and 13 more
- Volunteers
- 576 people
- Sponsor
- Novartis Pharmaceuticals
Implementing EAS/ESC Guideline Recommendation on Lp(a) Testing in Routine Practice
Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings
Lipoprotein(a) [Lp(a)] is recognised as an independent, non-modifiable genetic risk factor for cardiovascular (CV) disease. Current guidelines from the European Society of Cardiology (ESC) and the European Atherosclerosis Society…
- Trial name
- Lp(a)CCELERATE (NCT07508007)
- Where
- Germany
- Volunteers
- 4,500 people
- Sponsor
- Novartis Pharmaceuticals
HR+/HER2- Advanced or Metastatic Breast Cancer
Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China
This study aims to fill the current gap in data regarding HR+/HER2- ABC 1L treatment patterns and outcomes in the real-world setting in China, especially in the context of the widespread application of CDK4/6is and the lack of…
- Trial name
- NCT07476170
- Where
- China
- Volunteers
- 14,000 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy, Immunoglobulin A Nephropathy
A Study of Zigakibart in Adults With IgA Nephropathy
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
- Trial name
- NCT05852938
- Testing
- BION-1301
- Where
- 200 sites in United States, Argentina and 21 more
- Volunteers
- 383 people
- Sponsor
- Novartis Pharmaceuticals
Giant Cell Arteritis, Polymyalgia Rheumatica
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
This study will examine how intravenous (i.v.) Secukinumab will be processed in the body (pharmacokinetics [PK]) and whether it will be safe and tolerable after multiple doses of i.v.
- Trial name
- NCT06130540
- Testing
- Secukinumab
- Where
- 19 sites in United States, Czechia and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Epidemiology and Treatment of HR+/HER2- Breast Cancer in England
The aim of this study was to describe the epidemiology, treatment pathway, treatment access, wastage of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), and health care resource use among adults with hormone receptor positive…
- Trial name
- ROTOR (NCT07498413)
- Where
- United Kingdom
- Volunteers
- 218,677 people
- Sponsor
- Novartis Pharmaceuticals
Anaplastic Lymphoma Kinase (ALK)- Positive Tumors, Non-small Cell Lung Cancer (NSCLC)
Managed Access Programs for LDK378, Ceritinib
The purpose of this registration is to list Managed Access Programs (MAPs) related to LDK378, Ceritinib.
- Trial name
- NCT05100134
- Testing
- ceritinib
- Sponsor
- Novartis Pharmaceuticals
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (1 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metastatic solid tumors for whom a…
- Trial name
- NCT05868629
- Testing
- Non-investigational
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia in Chronic Phase
Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
This is a multicenter, non-interventional real-world study designed to assess the efficacy and safety of asciminib in patients with newly diagnosed CML.The study uses a prospective data collection design to gather baseline, pre…
- Trial name
- ASC4CN (NCT07375355)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
HR+HER2- Advanced Breast Cancer
A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian Federation
This is а prospective, non-interventional, primary data collection study to evaluate the effectiveness, safety and quality of life in older patients (≥65 years) with HR+HER2- advanced breast cancer receiving ribociclib with ET in…
- Trial name
- PARFENOPA (NCT06625333)
- Where
- 20 sites in Russia
- Volunteers
- 329 people
- Sponsor
- Novartis Pharmaceuticals
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of VAY736 alone or in combination with other therapies in patients with NHL in a platform trial.
- Trial name
- NCT04903197
- Testing
- VAY736, lenalidomide
- Where
- 10 sites in Australia, China and 5 more
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer, Gastroesophageal Cancer
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer…
- Conditions
- Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
- Trial name
- NCT03798626
- Testing
- Gevokizumab, Bevacizumab, Modified FOLFOX6
- Where
- 34 sites in United States, Australia and 13 more
- Volunteers
- 167 people
- Sponsor
- Novartis Pharmaceuticals
Giant Cell Arteritis (GCA)
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
- Trial name
- GCAptAIN (NCT04930094)
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 104 sites in United States, Argentina and 25 more
- Volunteers
- 354 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis, Knee
Safety and Efficacy of RHH646 for Knee Osteoarthritis
The purpose of this study was to evaluate the articular cartilage-regenerating capacity of RHH646 in the knee as well as to assess safety and tolerability in participants with knee osteoarthritis.
- Trial name
- NCT05816395
- Testing
- RHH646
- Where
- 10 sites in United States, Argentina and 3 more
- Volunteers
- 82 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis, Knee
A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA
The purpose of the study was to find out if the investigational treatment named QUC398 had beneficial effects on osteoarthritis (OA) knee pain and knee cartilage, and if it was safe and tolerated.
- Trial name
- NCT05462990
- Testing
- QUC398
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 101 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer (NSCLC)
Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
The purpose of the study was to learn whether the study treatment (capmatinib), which already shows efficacy and safety in non-Chinese patients, could help Chinese patients with controlling their lung cancer in a safe way.
- Trial name
- GeoMETry-C (NCT04677595)
- Testing
- Capmatinib
- Where
- 17 sites in China
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Symptomatic Knee Osteoarthritis
Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis
This was a double-blinded, two-arm, phase 2a study to assess efficacy, safety and tolerability of DFV890 in participants with symptomatic knee osteoarthritis.
- Trial name
- NCT04886258
- Testing
- DFV890
- Where
- 31 sites in United States, Argentina and 6 more
- Volunteers
- 115 people
- Sponsor
- Novartis Pharmaceuticals
Adult Onset Still's Disease
Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD
This study was designed to evaluate the efficacy and safety of canakinumab administered subcutaneously every 4 weeks for at least 48 weeks in Japanese patients with Adult-Onset Still's Disease (AOSD).
- Trial name
- NCT04717635
- Testing
- Canakinumab
- Where
- 9 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Prostate Cancer
Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)
This non-interventional, observational, multicenter, prospective cohort study is designed to investigate the treatment patterns of mPC patients treated with lutetium (177Lu) vipivotide tetraxetan, as well as their clinical…
- Trial name
- PSMAreal (NCT07290270)
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.